Beta adrenergic blocking agents for open-angle glaucoma.
Beta adrenergic blocking agents have gained wide acceptance among practitioners and patients alike as extremely useful drugs for the treatment of open-angle glaucoma. This new class of antiglaucoma agents usually is effective in reducing elevated intraocular pressure and is generally well tolerated. This paper is intended to provide an understanding of the ophthalmic beta adrenergic blocking agents to optometrists who are actively involved in the treatment of glaucoma and/or in the monitoring of glaucoma patients. The clinical pharmacology of the three FDA-approved beta blockers -- timolol, levobunolol, and betaxolol, is evaluated and the drugs are compared.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D015784:Betaxolol; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D002040:Levobunolol / Q000627:therapeutic use; D011412:Propanolamines / Q000627:therapeutic use; D013999:Timolol / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D013999:Timolol; D002040:Levobunolol; D015784:Betaxolol